

ASX ANNOUNCEMENT

Date of Annual General Meeting 2022

9 September 2022, Melbourne, Australia

Exopharm Limited (ASX:EX1) advises that the Annual General Meeting (**AGM**) of Exopharm is scheduled for Thursday 24 November 2022.

Further information about the AGM will be set out in the Notice of Meeting which will be released to the market and available to shareholders on or around 25 October 2022.

In accordance with Clause 6.2(f) of the Company's Constitution, nominations for election of directors at the AGM must be received no less than 35 Business Days before the meeting, being no later than 6 October 2022.

This announcement has been authorised for release by the Chair of the Company.

Company and Media Enquiries:

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Ian Dixon
Managing Director
Tel: +61 418 561 907
ian.dixon@exopharm.com

ABOUT EXOPHARM

Exopharm (ASX:EX1) is at the forefront of transformative medicines using exosomes or extracellular vesicles (EVs) and is pursuing a product pipeline-driven platform strategy.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments.

Exosome delivery of DNA and other gene therapies into the nucleus of the patient's cells may improve treatment of inherited medical conditions. Exosomes can also be used to deliver small molecule drugs, mRNA and other modern medicines.

Exosomes are an alternative means of drug delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell- penetrating peptides, viral vectors and liposomes. Exopharm's exosome

technologies solve important needs for the success of exosome medicines – **LEAP** manufacturing technology, **LOAD** API loading technologies and **EVPS** tropism technologies.

Exopharm technology platforms will underpin its own pipeline of exosome medicines – each aimed at delivering a transformative medicine for an unmet medical need.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘aims’, ‘plans’, ‘can’ or ‘expects’. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm’s control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.